{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:05:01Z","timestamp":1790996701421,"version":"4.1.0"},"reference-count":30,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>(1) Background: Subcutaneous apomorphine infusion (SCAI) is one of the three main treatment options for motor fluctuations in advanced Parkinson\u2019s disease (PD). The adherence to SCAI is generally considered to be low due to adverse events and because it is perceived as a treatment option to be used for a limited period only. We evaluated the reasons for discontinuation of SCAI in relation to when patients stopped treatment. (2) Methods: We reviewed the medical records of PD patients treated with SCAI at a single center, capturing patient demographics and the reasons for cessation of SCAI. (3) Results: 101 patients were included in the analysis, with a median time on treatment of 6.34 years. The main reasons for stopping SCAI were adverse events, death, and dissatisfaction with treatment. In the first 6 years of treatment, the predominant side effects leading to discontinuation were somnolence and hallucinations. (4) Conclusions: We suggest that SCAI can be an effective long-term treatment option for advanced PD, but it requires careful patient selection, a high level of communication with the patient and carer, and rigorous monitoring of the effects of treatment and for any adverse events so they can be promptly managed.<\/jats:p>","DOI":"10.3390\/jpm11060525","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T12:08:55Z","timestamp":1623154135000},"page":"525","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Continuous Subcutaneous Apomorphine Infusion in Parkinson\u2019s Disease: A Single-Center, Long-Term Follow-Up Study of the Causes for Discontinuation"],"prefix":"10.3390","volume":"11","author":[{"given":"Tove","family":"Henriksen","sequence":"first","affiliation":[{"name":"Department of Neurology, University Hospital of Bispebjerg, 2400 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Staines","sequence":"additional","affiliation":[{"name":"Sigma Statistical Services, Balmullo KY16 0BD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/WNL.36.11.1528","article-title":"Low-dose L-dopa therapy in Parkinson\u2019s disease: A 6-year follow-up study","volume":"36","author":"Poewe","year":"1986","journal-title":"Neurology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of the motor complications of Parkinson\u2019s disease on the quality of life","volume":"20","author":"Chapuis","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/jnnp.53.11.1004","article-title":"Comparison of motor response to apomorphine and levodopa in Parkinson\u2019s disease","volume":"53","author":"Kempster","year":"1990","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(87)91660-6","article-title":"Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations","volume":"329","author":"Stibe","year":"1987","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H","article-title":"Apomorphine: An underutilized therapy for Parkinson\u2019s disease","volume":"15","author":"Poewe","year":"2000","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00415-012-6798-6","article-title":"Selecting deep brain stimulation or infusion therapies in advanced Parkinson\u2019s disease: An evidence-based review","volume":"260","author":"Volkmann","year":"2013","journal-title":"J. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","article-title":"Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): A multicentre, double-blind, randomised, placebo-controlled trial","volume":"17","author":"Katzenschlager","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s10072-019-03920-5","article-title":"Continuous subcutaneous apomorphine infusion in Parkinson\u2019s disease: Causes of discontinuation and subsequent treatment strategies","volume":"40","author":"Olivola","year":"2019","journal-title":"Neurol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/imj.13378","article-title":"Long-term adherence to apomorphine infusion in patients with Parkinson disease: A 10-year observational study","volume":"47","author":"Kimber","year":"2017","journal-title":"Intern. Med. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/mds.10281","article-title":"Apomorphine monotheraphy in the treatment of refractory motor complications of parkinson\u2019s disease: Long-term follow-up study of 64 patients","volume":"17","author":"Manson","year":"2002","journal-title":"Mov. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.22063","article-title":"Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson\u2019s disease with motor fluctuations: A multicenter study","volume":"23","year":"2008","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-004-0547-4","article-title":"A 10 year retrospective audit of long-term apomorphine use in Parkinson\u2019s disease","volume":"251","author":"Tyne","year":"2004","journal-title":"J. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/jnnp.65.5.709","article-title":"Subcutaneous apomorphine in late stage Parkinson\u2019s disease: A long term follow up","volume":"65","author":"Pietz","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s00415-017-8477-0","article-title":"Continuous subcutaneous apomorphine infusion in advanced Parkinson\u2019s disease: 10-year experience with 230 patients","volume":"264","author":"Sesar","year":"2017","journal-title":"J. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: A clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2165\/00019053-200119120-00001","article-title":"Accounting for Noncompliance in Pharmacoeconomic Evaluations","volume":"19","author":"Hughes","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/mdc3.12592","article-title":"Challenges in PD Patient Management After DBS: A Pragmatic Review","volume":"5","author":"Rossi","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/archneur.62.8.noc40425","article-title":"Management of Referred Deep Brain Stimulation Failures: A Retrospective Analysis From 2 Movement Disorders Centers","volume":"62","author":"Okun","year":"2005","journal-title":"Arch. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.parkreldis.2010.09.005","article-title":"Measurement of patient centered outcomes in parkinson\u2019s disease: What do patients really want from their treatment?","volume":"17","author":"Nisenzon","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/WNF.0000000000000361","article-title":"Long-term Apomorphine Infusion Users Versus Short-term Users: An International Dual-center Analysis of the Reasons for Discontinuing Therapy","volume":"42","author":"Bhidayasiri","year":"2019","journal-title":"Clin. Neuropharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jnnp.64.5.573","article-title":"Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson\u2019s disease","volume":"64","author":"Colzi","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF00812157","article-title":"The clinical use of apomorphine in Parkinson\u2019s disease","volume":"239","author":"Steiger","year":"1992","journal-title":"J. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2015.11.013","article-title":"Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson\u2019s disease patients","volume":"23","author":"Borgemeester","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.parkreldis.2017.09.025","article-title":"Continuous subcutaneous apomorphine infusion in Parkinson\u2019s disease patients with cognitive dysfunction: A retrospective long-term follow-up study","volume":"45","author":"Borgemeester","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1353-8020(97)00009-6","article-title":"Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment","volume":"3","author":"Ellis","year":"1997","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2020.12.024","article-title":"Long-term safety and efficacy of apomorphine infusion in Parkinson\u2019s disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study","volume":"83","author":"Katzenschlager","year":"2021","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1136\/jnnp-2012-302741","article-title":"Comparison of patient rated treatment response with measured improvement in Parkinson\u2019s disease","volume":"83","author":"Davidson","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/mds.20602","article-title":"Suboptimal medication adherence in Parkinson\u2019s disease","volume":"20","author":"Grosset","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0022-3999(81)90043-X","article-title":"Patients\u2019 satisfaction with communication in neurological outpatient clinics","volume":"25","author":"Fitzpatrick","year":"1981","journal-title":"J. Psychosom. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.parkreldis.2015.05.014","article-title":"Long-term response to continuous duodenal infusion of levodopa\/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry","volume":"21","author":"Buongiorno","year":"2015","journal-title":"Parkinsonism Relat. Disord."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/6\/525\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:12:05Z","timestamp":1760163125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/6\/525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["jpm11060525"],"URL":"https:\/\/doi.org\/10.3390\/jpm11060525","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]}}}